CC
DAWN

Commodore Capital’s Day One Biopharmaceuticals DAWN Stock Holding History

Commodore Capital’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-739,661
Closed -$9.08M – 34
2023
Q3 		$9.08M Hold
739,661
– – 1.06% 24
2023
Q2 		$8.83M Hold
739,661
– – 0.99% 22
2023
Q1 		$9.89M Hold
739,661
– – 1.51% 21
2022
Q4 		$15.9M Hold
739,661
– – 2.4% 16
2022
Q3 		$14.8M Hold
739,661
– – 2.38% 15
2022
Q2 		$13.2M Buy
+739,661
New +$7.64M 2.8% 14

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Commodore Capital's DAWN Position: Q4 2023 in Review

Commodore Capital sold out of Day One Biopharmaceuticals (DAWN) in Q4 2023, closing a stake of 739,661 shares — an estimated $9.08M sold.

Commodore Capital first reported a position in DAWN in Q2 2022 and held it in 6 quarters. The position peaked at $15.9M in Q4 2022. 139 funds tracked by Wall St. Rank hold DAWN as of Q4 2023.

  • Commodore Capital reported no remaining Day One Biopharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Commodore Capital sold 739,661 Day One Biopharmaceuticals shares in Q4 2023, an estimated $9.08M.
  • Commodore Capital first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 6 quarters.
  • Commodore Capital's Day One Biopharmaceuticals position peaked at $15.9M in Q4 2022.
  • 139 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2023.

Based on Commodore Capital's 13F filing for Q4 2023, filed 14 Feb 2024.